8 completed, 1 no longer available. 4 Not applicable, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Vasoactive Intestinal Peptide: new trials by email Literature Review of Vasoactive Intestinal Peptide trials Research Report on Vasoactive Intestinal Peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Aviptadil, Aviptadil Placebo, Corticosteroid - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 471 | 2021-04-20 | 2025-10-09 |
| ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Remdesivir, Remdesivir Placebo, Aviptadil - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 473 | 2021-04-20 | 2025-10-24 |
| The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients Vasoactive Intestinal Polypeptide (VIP), Sterile saline - Migraine, Pain | Not applicable | Completed | Danish Headache Center | 21 | 2020-05-19 | 2020-10-20 |
| The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers Vasoactive Intestinal Peptide (VIP) and Saline - Headache Disorders | Not applicable | Completed | Danish Headache Center | 12 | 2019-06-14 | 2020-08-20 |
| Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance Pituitary Adenylate Cyclase-Activating Polypeptide-38, Vasoactive Intestinal Peptide - Migraine Without Aura | Not applicable | Completed | Glostrup University Hospital, Copenhagen | 24 | 2011-05-01 | 2012-08-29 |
| Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in Migraineurs Vasoactive intestinal peptide - Headache, Migraine | Not applicable | Completed | Danish Headache Center | 12 | 2004-10-01 | 2006-01-09 |
| Vasoactive Intestinal Peptide in COPD Vasoactive Intestinal Peptide (VIP) - COPD, Pulmonary Hypertension | Completed | Medical University of Vienna | 34 | 2003-06-01 | 2007-04-24 | |
| Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis vasoactive intestinal peptide - Sepsis, Respiratory Distress Syndrome | Phase 1 | Completed | Stony Brook University | 18 | 1998-09-01 | 2022-05-04 |
| ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) ZYESAMI (aviptadil acetate) - Critical COVID-19 With Respiratory Failure | No longer available | APR Applied Pharma Research s.a. | 2023-02-03 |
Migraine Disorders (3) · COVID-19 (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2) · Aneurysm (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Communicable Diseases (1) · Headache (1) · Headache Disorders (1) · Hypertension, Pulmonary (1)
Danish Headache Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · APR Applied Pharma Research s.a. (1) · Glostrup University Hospital, Copenhagen (1) · Medical University of Vienna (1) · Stony Brook University (1)
Denmark (4) · United States (4)
Prof. James Neaton (2) · Samuel Brown, MD (2) · Faisal Amin, M.D. (1) · Jes Olesen, MD, PhD (1) · Jonathan C Javitt, MD, MPH (1) · Lutz-Henning Block, MD (1) · Messoud Ashina, MD, PhD (1) · Sami I. Said (1)
PMID 35432170, PMID 32594760, PMID 34357396, PMID 34825704, PMID 36695483, PMID 37348524